title: The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.
abstract: OBJECTIVE
  Androgen deprivation therapy may promote the development of the metabolic syndrome in patients with prostate cancer. We assessed the prevalence of the full metabolic syndrome and its components during the first year of androgen deprivation therapy.
  
  
  METHODS
  This observational, multicenter, prospective study included 539 patients with prostate cancer scheduled to receive 3-month depot luteinizing hormone-releasing hormone analogs for more than 12 months. Waist circumference, body mass index, lipid profile, blood pressure and fasting glucose were evaluated at baseline and after 6 and 12 months. The metabolic syndrome was assessed according to NCEP ATP III criteria (2001) and 4 other definitions (WHO 1998, AACE 2003, AHA/NHLBI 2005 and IDF 2005).
  
  
  RESULTS
  At 6 and 12 months after the initiation of androgen deprivation therapy, significant increases were observed in waist circumference, body mass index, fasting glucose, triglycerides, total cholesterol, and high-density and low-density lipoprotein cholesterol. No significant changes in blood pressure 130/85 or greater were detected. A nonsignificant increase of 3.9% in the prevalence of the full metabolic syndrome (ATP III) was observed (22.9% at baseline vs 25.5% and 26.8% at 6 and 12 months, respectively). The prevalence of the metabolic syndrome at baseline varied according to the definition used, ranging from 9.4% (WHO) to 50% (IDF). At 12 months significant increases in prevalence were observed with the WHO (4.1%) and AHA/NHLBI (8.1%) definitions.
  
  
  CONCLUSIONS
  Androgen deprivation therapy produces significant early effects on waist circumference, body mass index, fasting glucose, triglycerides and cholesterol. The prevalence of and increase in the metabolic syndrome depend on the defining criteria. Counseling patients on the prevention, early detection and treatment of specific metabolic alterations is recommended.
authors.affiliation: Department of Urology, Hospital Vall d'Hebron and Universitat Autónoma de Barcelona, Barcelona, Spain. Electronic address: jmorote@vhebron.net.
authors.forename: Juan
authors.initials: J
authors.lastname: Morote
authors.affiliation: Department of Radiation Oncology, Hospital Clínico Universitario Santiago de Compostela, A Coruña, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Gómez-Caamaño
authors.affiliation: Department of Urology, Hospital Universitario Puerta del Mar, Cadiz, Spain.
authors.forename: José L
authors.initials: JL
authors.lastname: Alvarez-Ossorio
authors.affiliation: Department of Urology, Hospital Universitario Povisa, Pontevedra, Spain.
authors.forename: Daniel
authors.initials: D
authors.lastname: Pesqueira
authors.affiliation: Department of Urology, Hospital Universitario La Paz, Madrid, Spain.
authors.forename: Angel
authors.initials: A
authors.lastname: Tabernero
authors.affiliation: Department of Urology, Hospital A Coruña, A Coruña, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Gómez Veiga
authors.affiliation: Department of Urology, Hospital del Mar, Barcelona, Spain.
authors.forename: José A
authors.initials: JA
authors.lastname: Lorente
authors.affiliation: Department of Radiation Oncology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
authors.forename: Mariano
authors.initials: M
authors.lastname: Porras
authors.affiliation: Department of Urology, Hospital General Universitario de Alicante, Alicante, Spain.
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Lobato
authors.affiliation: Department of Urology, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
authors.forename: María J
authors.initials: MJ
authors.lastname: Ribal
authors.affiliation: Department of Urology, Hospital Vall d'Hebron and Universitat Autónoma de Barcelona, Barcelona, Spain.
authors.forename: Jacques
authors.initials: J
authors.lastname: Planas
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000453:epidemiology; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone
keywords: androgens; metabolic syndrome X; prostatic neoplasms